We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 103

Punitive damages not available under section 8 of the PM (NOC) Regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

The Supreme Court of Canada has refused Teva’s application for leave to appeal the decision of the Federal Court of Appeal which had upheld an order

New developments on the patent “utility” debate in Canada

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

There have been a number of notable developments in recent weeks in respect of patent utility law in Canada

Canada catching up with the world? Parliament proposes changes to its patent and design laws

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 11 2014

On October 23, 2014, the Canadian Government introduced an omnibus budget bill. The Bill, which implements various tax measures and amends several

STELARA injunction overturned: biologics infringementinvalidity action is remitted back to the Federal Court for a new trial before a different judge

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 3 2014

The Federal Court of Appeal allowed Janssen’s appeals of three decisions of Mr. Justice Hughes that resulted in an injunction order against Janssen

Supreme Court to consider section 8 damage quantification

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 31 2014

The Supreme Court of Canada announced yesterday that it has granted leave to appeal the decision of the Federal Court of Appeal in a proceeding

IP enforcement guidelines and patent litigation settlement agreements

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 23 2014

The Competition Bureau has released the final version of its updated Intellectual Property Enforcement Guidelines, which set out its approach to

Competition Bureau releases updated IP enforcement guidelines and white paper on patent litigation settlement agreements

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 7 2014

The Competition Bureau made several significant announcements in September that affect the pharmaceuticals and life sciences sectors. On September 18

Consolidated CETA text released Patent term restoration and innovator right of appeal in PM(NOC) proceedings part of EU trade agreement

  • Norton Rose Fulbright LLP
  • -
  • Canada, European Union
  • -
  • October 6 2014

On September 26, 2014, after five years of negotiations, the Comprehensive Economic and Trade Agreement (CETA) consolidated text was finally released

Pharma in brief - Federal Court of Appeal overturns Federal Court decision and dismisses application for prohibition order

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 2 2014

Pharmascience Inc. (Pharmascience) appealed from the decision of Justice O’Keefe of the Federal Court (reported as AstraZeneca Canada Inc. v

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®